Tourmaline Bio (TRML) Competitors $19.16 +0.16 (+0.84%) As of 03:57 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TRML vs. INDV, APGE, IRON, BHC, BEAM, ARQT, BHVN, SDGR, EWTX, and JANXShould you be buying Tourmaline Bio stock or one of its competitors? The main competitors of Tourmaline Bio include Indivior (INDV), Apogee Therapeutics (APGE), Disc Medicine (IRON), Bausch Health Companies (BHC), Beam Therapeutics (BEAM), Arcutis Biotherapeutics (ARQT), Biohaven (BHVN), Schrödinger (SDGR), Edgewise Therapeutics (EWTX), and Janux Therapeutics (JANX). These companies are all part of the "pharmaceutical products" industry. Tourmaline Bio vs. Indivior Apogee Therapeutics Disc Medicine Bausch Health Companies Beam Therapeutics Arcutis Biotherapeutics Biohaven Schrödinger Edgewise Therapeutics Janux Therapeutics Tourmaline Bio (NASDAQ:TRML) and Indivior (NASDAQ:INDV) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their community ranking, risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends. Does the media favor TRML or INDV? In the previous week, Tourmaline Bio and Tourmaline Bio both had 7 articles in the media. Indivior's average media sentiment score of 1.35 beat Tourmaline Bio's score of 1.21 indicating that Indivior is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tourmaline Bio 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Indivior 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation & earnings, TRML or INDV? Indivior has higher revenue and earnings than Tourmaline Bio. Indivior is trading at a lower price-to-earnings ratio than Tourmaline Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTourmaline BioN/AN/A-$42.12M-$3.21-6.11Indivior$1.17B1.60$2M-$0.31-43.67 Is TRML or INDV more profitable? Tourmaline Bio has a net margin of 0.00% compared to Indivior's net margin of -3.96%. Tourmaline Bio's return on equity of -20.97% beat Indivior's return on equity.Company Net Margins Return on Equity Return on Assets Tourmaline BioN/A -20.97% -20.56% Indivior -3.96%-241.73%15.09% Which has more risk and volatility, TRML or INDV? Tourmaline Bio has a beta of 2.05, indicating that its share price is 105% more volatile than the S&P 500. Comparatively, Indivior has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500. Do insiders & institutionals believe in TRML or INDV? 91.9% of Tourmaline Bio shares are held by institutional investors. Comparatively, 60.3% of Indivior shares are held by institutional investors. 13.0% of Tourmaline Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts recommend TRML or INDV? Tourmaline Bio currently has a consensus target price of $49.33, indicating a potential upside of 151.51%. Indivior has a consensus target price of $15.00, indicating a potential upside of 10.81%. Given Tourmaline Bio's higher possible upside, equities research analysts plainly believe Tourmaline Bio is more favorable than Indivior.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tourmaline Bio 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Indivior 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Does the MarketBeat Community favor TRML or INDV? Tourmaline Bio received 13 more outperform votes than Indivior when rated by MarketBeat users. However, 100.00% of users gave Indivior an outperform vote while only 96.00% of users gave Tourmaline Bio an outperform vote. CompanyUnderperformOutperformTourmaline BioOutperform Votes2496.00% Underperform Votes14.00%IndiviorOutperform Votes11100.00% Underperform VotesNo Votes SummaryTourmaline Bio beats Indivior on 9 of the 17 factors compared between the two stocks. Get Tourmaline Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for TRML and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRML vs. The Competition Export to ExcelMetricTourmaline BioBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$503.17M$3.11B$5.60B$8.63BDividend YieldN/A1.59%5.27%4.19%P/E Ratio-6.9533.6327.3220.13Price / SalesN/A476.07411.80160.09Price / CashN/A168.6838.2534.64Price / Book1.953.497.154.74Net Income-$42.12M-$72.35M$3.23B$247.80M7 Day Performance4.73%8.24%3.47%2.70%1 Month Performance29.99%22.80%12.95%10.03%1 Year Performance25.58%-16.01%32.16%15.42% Tourmaline Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRMLTourmaline Bio2.1629 of 5 stars$19.16+0.8%$49.33+157.5%+25.0%$491.23MN/A-6.7844Positive NewsAnalyst RevisionINDVIndivior1.984 of 5 stars$12.46-3.1%$15.00+20.4%-19.3%$1.72B$1.17B-35.601,164Positive NewsAPGEApogee Therapeutics2.0557 of 5 stars$36.33-0.8%$94.60+160.4%-4.3%$1.67BN/A-15.0191IRONDisc Medicine1.8605 of 5 stars$47.73+2.2%$98.80+107.0%+33.6%$1.65BN/A-11.9930Positive NewsAnalyst ForecastInsider TradeAnalyst RevisionBHCBausch Health Companies4.5745 of 5 stars$4.49-1.0%$7.42+65.4%-19.5%$1.64B$9.73B-37.3719,900Positive NewsBEAMBeam Therapeutics3.0457 of 5 stars$16.19+2.3%$48.75+201.1%-25.9%$1.63B$63.58M-9.20510Analyst RevisionARQTArcutis Biotherapeutics2.0066 of 5 stars$13.48+3.4%$18.80+39.5%+84.2%$1.61B$212.82M-7.53150Positive NewsBHVNBiohaven2.7911 of 5 stars$15.62+5.4%$59.46+280.8%-52.2%$1.59BN/A-1.67239Analyst RevisionHigh Trading VolumeSDGRSchrödinger1.5661 of 5 stars$21.69+0.3%$32.80+51.2%+22.4%$1.59B$230.49M-9.27790EWTXEdgewise Therapeutics3.1058 of 5 stars$14.69+2.9%$40.22+173.8%-9.8%$1.55BN/A-9.7960JANXJanux Therapeutics1.5855 of 5 stars$25.01+5.1%$95.25+280.8%-39.5%$1.48B$9.34M-21.3830Positive NewsAnalyst Revision Related Companies and Tools Related Companies Indivior Alternatives Apogee Therapeutics Alternatives Disc Medicine Alternatives Bausch Health Companies Alternatives Beam Therapeutics Alternatives Arcutis Biotherapeutics Alternatives Biohaven Alternatives Schrödinger Alternatives Edgewise Therapeutics Alternatives Janux Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TRML) was last updated on 6/11/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tourmaline Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tourmaline Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TRML Stock Free TRML Stock Alerts